<DOC>
	<DOCNO>NCT00022490</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Imatinib mesylate may stop growth cancer cell block enzymes necessary cancer cell growth . PURPOSE : This phase II trial study give imatinib mesylate together cytarabine see well work treat patient chronic phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Imatinib Mesylate Plus Cytarabine Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine rate duration complete major minor cytogenetic response 6 12 month treatment patient chronic phase chronic myelogenous leukemia treat imatinib mesylate cytarabine . - Determine rate duration complete hematologic responses 6 12 month treatment patient treat regimen . - Determine rate molecular response patient complete cytogenetic response 6 12 month treatment regimen . - Determine pharmacokinetics regimen patient . - Determine safety regimen patient . OUTLINE : This nonrandomized , open-label , multicenter study . Patients receive oral imatinib mesylate day 1-28 cytarabine subcutaneously day 15-28 . Courses repeat every 28 day 12 month absence disease progression unacceptable toxicity . Patients follow 30-60 day . PROJECTED ACCRUAL : A total 15 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytogenetically confirm chronic phase chronic myelogenous leukemia ( CML ) Less 15 % blast peripheral blood bone marrow Less 30 % blast promyelocytes peripheral blood bone marrow Less 20 % basophil blood bone marrow Platelet count least 100,000/mm^3 Philadelphia chromosome positive No 6 month since initial diagnosis No presence leukemia beyond bone marrow , blood , liver , spleen ( i.e. , chloroma ) Refused allogeneic stem cell transplantation firstline therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 3 month study participation No serious uncontrolled medical condition No history noncompliance medical regimen potential unreliability PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior biologic therapy CML Chemotherapy : No prior chemotherapy CML except hydroxyurea Concurrent hydroxyurea control blood count first 3 month treatment allow No concurrent chemotherapy Endocrine therapy : No prior endocrine therapy CML Radiotherapy : No prior radiotherapy CML Surgery : Not specify Other : More 28 day since prior investigational anticancer agent Prior anagrelide hydrochloride CML allow Concurrent anagrelide hydrochloride control blood count first 3 month treatment allow No concurrent grapefruit juice grapefruit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
</DOC>